L3VLUP
ProSign in

GRFS · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GRFSJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GRFS
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterGRFSJNJ
Q3 20208 holders, $472m30 holders, $26.2bn
Q4 20207 holders, $477m32 holders, $26.6bn
Q1 20217 holders, $471m31 holders, $25.3bn
Q2 20216 holders, $442m37 holders, $25.6bn
Q3 20216 holders, $357m40 holders, $24.1bn
Q4 20215 holders, $301m33 holders, $25.2bn
Q1 20224 holders, $281m35 holders, $28.2bn
Q2 20225 holders, $406m33 holders, $26.9bn
Q3 20224 holders, $162m36 holders, $25.4bn
Q4 20224 holders, $304m35 holders, $27.6bn
Q1 20234 holders, $294m42 holders, $24.5bn
Q2 20235 holders, $391m38 holders, $25.0bn
Q3 20235 holders, $404m37 holders, $18.9bn
Q4 20235 holders, $510m31 holders, $19.0bn
Q1 20245 holders, $266m32 holders, $19.7bn
Q2 20245 holders, $249m35 holders, $20.4bn
Q3 20246 holders, $320m28 holders, $22.3bn
Q4 20243 holders, $185m37 holders, $20.4bn
Q1 20253 holders, $178m32 holders, $20.5bn
Q2 20255 holders, $341m31 holders, $18.4bn
Q3 20254 holders, $290m32 holders, $23.7bn
Q4 20253 holders, $240m29 holders, $27.8bn
Q1 20263 holders, $199m34 holders, $35.6bn
Q2 20261 holders, $162m33 holders, $39.1bn
GRFS

Grifols SA

Holders
3
Reported value
$240m
Buyers
5
Sellers
7

Breadth -2 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GRFS (2)

Farallon Capital Management LLC, Harris Associates LP

Only JNJ (28)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, T. Rowe Price Associates Inc, and 3 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →